Motif BioSciences

Richard C. E. Morgan, Chairman

Prior to his involvement with the Company, Mr. Morgan was a founder and CEO of Amphion Capital Partners LLC (the predecessor company) and VennWorks LLC. Mr. Morgan was also the Managing General Partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP) a position which he retains, although the partnership is no longer active. Before joining Wolfensohn, Mr. Morgan spent 15 years with Schroders plc, a British merchant bank, where he was a member of the board of the merchant bank and head of the Schroder Strategy Group, which he founded. Mr. Morgan, a British citizen, was raised in Kenya and educated in England. He graduated with a B. Engineering First Class Honors from the University of Auckland, New Zealand. In 1982 he completed the Advanced Management Program at the Harvard Business School. He has been a member of the board of directors of Celgene Corporation since it was founded in 1986; Celgene is now one of the top five biotechnology companies in the world.

Zaki Hosny, CEO and Deputy Chairman

Zaki Hosny is CEO and Deputy Chairman of Motif BioSciences, responsible for all aspects of the management and operations of the company. Prior to joining Motif in July 2006, Mr. Hosny spent over 35 years in the global pharmaceutical industry working for Merck & Co., Inc. He held senior management positions in the United States and several European countries in general management, marketing and government relations. In addition he has extensive experience of the clinical research and new products planning functions within the pharmaceutical industry, and of negotiating and partnering with private and governmental bodies.

Mr. Hosny has an M.A. (Honours) degree from Cambridge University.

Joel Claiborne Stephens, Ph.D., SVP and Chief Scientific Officer
Joel Claiborne “Clay” Stephens is SVP and Chief Scientific Officer of Motif BioSciences. Previously, Clay was Vice President of Genetics and Executive Director of Population Genomics at Genaissance Pharmaceuticals (Nasdaq: GNSC) in New Haven, CT. Prior to that, Clay had served as a Principal Investigator, Head of Bioinformatics Group, and a Senior Staff Fellow at the National Institute of Health, NCI, DBS Laboratory of Genomic Diversity. Previously, he was a Senior Research Associate at the Yale-HHMI Human Gene Mapping Library.

Clay brings to Motif extensive experience in team building from the start-up through IPO stages, as well as experience with scientific and investor presentations, international partnering, and IP development. He has been widely published, including in Science.

Robert Bertoldi, Chief Financial Officer

Mr. Bertoldi is CFO of Motif BioSciences and is also Co-founder, President and CFO of Amphion Innovations plc. Mr. Bertoldi is also a Co-founder of VennWorks LLC and is Managing Member of Amphion Partners LLC the General Partner of Amphion Ventures L.P. Prior to founding VennWorks and Amphion Mr. Bertoldi served as Chief Financial Officer for James D. Wolfensohn, Inc. and Hambro America Inc.

Mr. Bertoldi has over 20 years experience in the venture capital industry. He has been directly involved in raising and investing over $250 million in venture capital funds. Mr. Bertoldi has extensive knowledge of deal structuring, mergers and acquisitions, divestitures, debt restructuring, public offerings, and work-outs.

Kevin Arnold, Ph.D., Executive Director, Genomics

Kevin Arnold is Executive Director, Genomics of Motif BioSciences. Previously, Dr. Arnold was Executive Director- Worldwide Operations at Genaissance Pharmaceuticals (Nasdaq: GNSC) in New Haven, CT. Prior to that, Dr. Arnold was Senior Director- Molecular Biology at Beckman Coulter, Inc. in Woburn, MA.

Dr. Arnold brings to Motif hands-on experience in start-up management and operations, as well as in project management and the development and build-out of high-throughput genetics facilities in the Arabian Gulf. Dr. Arnold was educated at the University College of North Wales, Tufts University and the University of Aberdeen.

Dr. Faisal H. Al-Refaei, Regional Director (Middle East)

Dr. Faisal H. Al-Refaei is the Regional Director of Motif BioSciences and for Amphion Innovations plc. for the Middle East region. Having strong relationships with prominent figures and families in the Middle East, Dr. Al-Refaei has worked on establishing and expanding Motif's business and academic ties to the Middle East as well as managing its day-to-day activities in this region. Dr. Al-Refaei has also been focusing on collaborating with Arabian Gulf-based institutions for genetic research projects.

While he is a medical practitioner by profession, with several years training in both the clinical field (in the UK and Kuwait) and in clinical governance in the healthcare field, Dr. Al-Refaei also has an MSc (Distinction) in health care management with a focus in quality management and improvement. Dr. Al-Refaei has also been involved with several family start-ups in Kuwait.

Dr. Al-Refaei was educated at Aberdeen University in Scotland where he received his MBChB and at the University of Wales, Swansea where he received his MSc.